Yang, J. C., Zhou, C., Jänne, P. A., Ramalingam, S. S., Kim, T. M., Riely, G. J., Spira, A. I., Piotrowska, Z., Mekhail, T., Garcia Campelo, M. R., Felip, E., Bazhenova, L., Jin, S., Kaur, M., Diderichsen, P. M., Gupta, N., Bunn, V., Lin, J., N. Churchill, E., Mehta, M., & Nguyen, D. (2023). characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer. Expert review of anticancer therapy, 23(1), 95–106. http://access.bl.uk/ark:/81055/vdc_100174902555.0x00001f